Tilray Brands, Inc. (NASDAQ:TLRY) will release earnings results for the first quarter, before the opening bell on Thursday, Oct. 9.Analysts expect the Leamington, Canada-based company to report a quarterly loss at 2 cents per share, versus a year-ago loss of 1 cent per share. Tilray Brands projects quarterly revenue of $204.55 million, compared to $200.04 million a year earlier, according to data from Benzinga Pro.On Aug. 28, Tilray Brands' medical division expanded its portfolio in Germany with three newly ...

Tilray stock price has been in a strong bull run in the past few months, making it one of the best-performing companies in Wall Street. TLRY jumped from a low of $0.355 in June and peaked at $1.88 thi... ...

The federal government closed up shop last week. You might not have known that if the stock market's performance was your guide: The S & P 500 finished the week at a record high on a six-day win streak . But the longer the shutdown in Washington drags on, the more attention Wall Street may start to give it. For now, the market calculus is relatively simple: a temporary shutdown is unlikely to materially alter the trajectory of the U.S. economy and corporate profits, considering that the hundreds of thousand ...

Core Insights - Tilray Brands' shares have surged approximately 300% since July, driven by optimism surrounding potential cannabis reform in the U.S. [1][6] - The upcoming earnings report on October 9 could serve as a catalyst for further stock movement, depending on the company's financial performance [2][4] Financial Performance - For the fiscal year ending May 31, Tilray reported net revenue of $821.3 million, a 4% year-over-year increase, although its core cannabis business saw a 9% decline, with sales dropping to $249 million [5] - Despite recent stock gains, Tilray's overall performance has been poor, with a 65% decline in stock value over the past five years [3][6] Market Challenges - The competitive landscape of the Canadian cannabis market poses significant challenges for Tilray and other producers, often leading to disappointing earnings reports [4][6] - The company's financial struggles and reliance on acquisitions to diversify revenue streams highlight ongoing vulnerabilities in its business model [7]

Market Overview - The stock market opened higher on Friday, with Wall Street remaining unfazed by the ongoing U.S. government shutdown [2] - The Nasdaq Composite and S&P 500 reached new intraday record highs despite the shutdown entering its second day [2] - The prediction market Kalshi indicates a 69% chance that the shutdown will last more than 10 days [2] Economic Reports - Investors are closely monitoring upcoming economic reports, although the reliability of government data is in question due to the shutdown [3] - Key reports expected next week include the CB Employment Trends Index, Exports, Imports, Trade Balance, Atlanta Fed GDP, and Consumer Credit [3] - Additional reports on FOMC Minutes, MBA Mortgage Applications, Construction Spending, Gasoline Production, Jobless Claims, and Wholesale Inventories are also anticipated [3] Earnings Reports - Several companies are scheduled to report earnings next week, including Constellation Brands, PepsiCo, Delta Air Lines, Levi Strauss, Tilray, and Unity Bancorp [4] - Specific earnings spotlight dates include Constellation Brands and Aehr Test Systems on October 6, and McCormick & Co on October 7 [5]

Core Viewpoint - Shares of Tilray Brands (NASDAQ: TLRY) surged approximately 40% this week, primarily driven by a pro-CBD video posted by former President Donald Trump on his Truth Social account [1][10]. Group 1: Market Reaction - The significant increase in Tilray's stock price was largely attributed to Trump's endorsement of CBD, which is known for its medical benefits without the psychoactive effects associated with other cannabis compounds [1][4]. - The post positively impacted the entire cannabis sector, as many companies, including Tilray, offer CBD products alongside their cannabis offerings [7][10]. Group 2: Company Developments - Tilray announced an expansion of its medical marijuana cannabis flower offerings in Germany, a market that has legalized both medical and recreational cannabis [2][8]. - The company has diversified its product portfolio to include recreational cannabis in Canada, medical cannabis in Europe, CBD beverages in various markets including the U.S., and recently, alcoholic beverages [7]. Group 3: Regulatory Context - Despite the legalization of CBD under the 2018 Farm Bill, cannabis remains illegal at the federal level in the U.S., and the FDA does not permit CBD in food supplements [5]. - The Trump administration's apparent support for CBD as a cost-effective alternative to expensive pharmaceuticals could signal a shift in regulatory attitudes towards cannabis products [6].

Core Viewpoint - Tilray Brands has experienced a significant stock increase of over 150% in the past six months, driven by optimism surrounding potential U.S. marijuana legalization, despite still being in penny stock territory at approximately $1.65 per share [2][3]. Group 1: Company Performance - Tilray Brands has lagged behind broader equities over the past five years as the cannabis industry has not met expectations [2]. - The company's diverse business operations include medical and recreational cannabis, pharmaceutical products, hemp-based wellness products, and craft brewing, with significant opportunities in the U.S. market if federal legalization occurs [4]. - The stock's recent surge is attributed to positive developments regarding U.S. marijuana legalization, including comments from President Trump about rescheduling cannabis [5][6]. Group 2: Market Challenges - The Canadian cannabis market, which legalized recreational use in late 2018, faced saturation and regulatory challenges, leading to a supply glut and inconsistent financial results for companies like Tilray [7][8][10]. - Despite the legalization in Canada, a significant portion of cannabis sales remained illicit, with illegal sales accounting for 24.3% of the market as of 2023, indicating ongoing challenges for legal operators [9]. Group 3: Future Considerations - The potential federal legalization of cannabis in the U.S. could change the market dynamics for Tilray, but the specifics of such legalization, including licensing and taxation, remain uncertain [11][12]. - The competitive landscape may also pose challenges, as larger companies with experience in regulated markets could enter the cannabis space [12].

Core Insights - Cannabis stocks experienced significant movement following President Trump's endorsement of cannabidiol (CBD) for seniors, highlighting potential health benefits [1] - Major marijuana stocks saw substantial gains, with Tilray Brands increasing by 42% and Aurora Cannabis by 25%, although some of these gains were later reversed [2] Company Overview - Constellation Brands is a significant shareholder in Canopy Growth, holding approximately 26 million shares through its shell company, which could represent about 14% of Canopy's stock if converted [3] - Constellation Brands is the third-largest beer company in the U.S., also producing high-end wine and spirits, with notable brands like Corona and Kim Crawford [4] Financial Performance - Constellation Brands has a market capitalization of $24.5 billion and has seen a year-to-date decline of 37% in 2025, underperforming competitors like Boston Beer and Molson Coors [5] - The stock is currently considered overvalued with a price-to-earnings ratio of 46.4, significantly higher than its 10-year median of 25.8 [5] Dividend Information - Constellation Brands offers a dividend yield of 3%, which is above the sector average of 1.9%, with the next payment scheduled for November 13, 2025 [6]

Core Insights - Tilray Brands (NASDAQ: TLRY) stock surged over 60% following President Donald Trump's video advocating for marijuana legalization for senior citizens, with potential Medicare coverage [1] - The stock experienced some pullback as momentum traders took profits, but rebounded with a 5.6% increase on Thursday [1] Group 1: Company Developments - Tilray is expanding its production of premium "Tilray Craft" cannabis in Germany, introducing five new cannabis flower products aimed at the medical marijuana market [3] - Currently, Tilray's European market is more significant than its U.S. market, with EMEA revenues exceeding $323 million annually compared to less than $274 million in the U.S. [5] Group 2: Financial Performance - Over the past year, Tilray has lost $2.2 billion, and its current market capitalization stands at approximately $2.2 billion [6] - Despite positive developments in production and potential market expansion, Tilray continues to face substantial financial losses [7]

Core Insights - Tilray Brands, Inc. is a significant player in the cannabis industry, known for its diverse product offerings and strategic acquisitions, including craft beer brands from Anheuser-Busch InBev, which has helped balance its revenue streams [1] - The company is set to release its quarterly earnings on October 9, 2025, with an estimated EPS of -$0.03, reflecting a 25% improvement year-over-year, and projected revenue of approximately $205.75 million, marking a 3.39% increase from the previous year [2][6] - Despite a recent stock price decline of 4.34% to $1.66, Tilray's stock has surged 38.4% over the past month, outperforming the Medical sector and the S&P 500, driven by political news and increased trading volume [3][6] Financial Metrics - Tilray's financial metrics indicate a complex valuation scenario, with a price-to-sales ratio of approximately 1.60 and an enterprise value to sales ratio of 1.61, suggesting reasonable valuation relative to sales [4] - The company has a negative price-to-earnings ratio and earnings yield, indicating current unprofitability, alongside a negative enterprise value to operating cash flow ratio, highlighting challenges in generating cash flow [4] - Despite these challenges, Tilray maintains a strong cash position, a low debt-to-equity ratio of 0.16, and a current ratio of 2.46, reflecting financial stability and the ability to cover short-term liabilities [5]